Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-057 (Adalimumab Biosimilar) vs Humira in Moderate to Severe Plaque Psoriasis
NCT02762955Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BCD-057 in plaque psoriasis (2 arms), sponsored by BIOCAD. Primary endpoint: Ratio of patients with PASI75 response at 16 weeks. Started Dec 2016; status: completed.
02
Drugs
BCD-057
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02762955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762955.